Published in CMAJ on August 12, 2008
Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55
Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med (2011) 1.16
Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone (2009) 1.04
Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol (2008) 0.83
Do proton pump inhibitors protect against cancer progression in GERD? Surg Today (2012) 0.81
Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. Acta Orthop (2012) 0.80
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int (2011) 0.79
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ (2008) 3.31
Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int (2006) 2.33
Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev (2008) 1.15
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int (2008) 2.59
Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology (2004) 2.40
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology (2004) 2.14
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology (2007) 1.94
Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem (2004) 1.91
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest (2002) 1.76
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol (2004) 1.67
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Assessment of gene-by-sex interaction effect on bone mineral density. J Bone Miner Res (2012) 1.58
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest (2003) 1.53
CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest (2016) 1.51
The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis (2011) 1.50
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res (2007) 1.38
Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res (2010) 1.37
Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology (2009) 1.33
Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ (2008) 1.33
Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol (2002) 1.32
The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab (2009) 1.32
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology (2003) 1.26
Defective bone mineralization and osteopenia in young adult FGFR3-/- mice. Hum Mol Genet (2003) 1.21
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19
Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum (2006) 1.18
Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res (2012) 1.18
Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women. J Bone Miner Res (2013) 1.16
Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res (2009) 1.15
Defects in mesenchymal stem cell self-renewal and cell fate determination lead to an osteopenic phenotype in Bmi-1 null mice. J Bone Miner Res (2010) 1.12
Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health (2012) 1.11
Impaired endochondral bone development and osteopenia in Gli2-deficient mice. Exp Cell Res (2004) 1.10
Dietary patterns in Canadian men and women ages 25 and older: relationship to demographics, body mass index, and bone mineral density. BMC Musculoskelet Disord (2010) 1.08
Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci U S A (2008) 1.08
Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. Am J Clin Nutr (2010) 1.06
Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology (2003) 1.04
Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum Mol Genet (2005) 1.04
Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology (2007) 1.02
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone (2008) 1.00
Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J Clin Endocrinol Metab (2013) 0.99
Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype. J Biol Chem (2003) 0.98
Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med (2003) 0.98
Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis (2011) 0.97
Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS. J Clin Densitom (2011) 0.97
LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res (2011) 0.96
In healthy adults, biological activity of vitamin D, as assessed by serum PTH, is largely independent of DBP concentrations. J Bone Miner Res (2014) 0.96
Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A (2012) 0.95
Early lethality in Hyp mice with targeted deletion of Pth gene. Endocrinology (2007) 0.95
Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab (2012) 0.95
1Alpha,25-dihydroxyvitamin D3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. J Bone Miner Res (2002) 0.95
On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J Bone Miner Res (2008) 0.93
Identification and functional characterization of a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia: modulation of clinical severity by vitamin D status. J Clin Endocrinol Metab (2007) 0.92
Distinctive anabolic roles of 1,25-dihydroxyvitamin D(3) and parathyroid hormone in teeth and mandible versus long bones. J Endocrinol (2009) 0.92
Changes in body mass index in Canadians over a five-year period: results of a prospective, population-based study. BMC Public Health (2007) 0.92
Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development. Bone (2004) 0.92
The calcium-sensing receptor mediates bone turnover induced by dietary calcium and parathyroid hormone in neonates. J Bone Miner Res (2011) 0.91
Defective female reproductive function in 1,25(OH)2D-deficient mice results from indirect effect mediated by extracellular calcium and/or phosphorus. Am J Physiol Endocrinol Metab (2010) 0.91
The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol (2009) 0.91
Exogenous PTH-related protein and PTH improve mineral and skeletal status in 25-hydroxyvitamin D-1alpha-hydroxylase and PTH double knockout mice. J Bone Miner Res (2005) 0.90
1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr Med Chem (2013) 0.90
Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complementary in inducing an anabolic effect on bone. J Bone Miner Res (2008) 0.89
Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. Am J Physiol Endocrinol Metab (2008) 0.89
Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1alpha-hydroxylase and parathyroid hormone null alleles. Endocrinology (2006) 0.88
The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice. Am J Physiol Endocrinol Metab (2012) 0.87
Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone (2004) 0.87
Parathyroid hormone contributes to regulating milk calcium content and modulates neonatal bone formation cooperatively with calcium. Endocrinology (2008) 0.86
Alterations in phosphorus, calcium and PTHrP contribute to defects in dental and dental alveolar bone formation in calcium-sensing receptor-deficient mice. Development (2010) 0.86
Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs (2004) 0.86
Impaired transforming growth factor-β (TGF-β) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1). J Biol Chem (2012) 0.85
TIP39/parathyroid hormone type 2 receptor signaling is a potent inhibitor of chondrocyte proliferation and differentiation. Am J Physiol Endocrinol Metab (2009) 0.85
Fibroblast growth factor 23 overexpression impacts negatively on dentin mineralization and dentinogenesis in mice. Clin Exp Pharmacol Physiol (2011) 0.84
Abnormal neurogenesis in the dentate gyrus of adult mice lacking 1,25-dihydroxy vitamin D3 (1,25-(OH)2 D3). Hippocampus (2010) 0.84
A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. J Med Genet (2013) 0.84
Meta-analysis of genome-wide studies identifies MEF2C SNPs associated with bone mineral density at forearm. J Med Genet (2013) 0.83
Do cyclooxygenase-2 knockout mice have primary hyperparathyroidism? Endocrinology (2004) 0.83
Endogenous PTH deficiency impairs fracture healing and impedes the fracture-healing efficacy of exogenous PTH(1-34). PLoS One (2011) 0.83
Cellular and molecular mechanisms of abnormal calcification following ischemia-reperfusion injury in human liver transplantation. Mod Pathol (2007) 0.82
The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum (2006) 0.82
Defective postnatal endochondral bone development by chondrocyte-specific targeted expression of parathyroid hormone type 2 receptor. Am J Physiol Endocrinol Metab (2012) 0.82
An efficient paradigm for genetic epidemiology cohort creation. PLoS One (2010) 0.82
Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice. Bone (2010) 0.82
1,25-Dihydroxyvitamin D₃ contributes to regulating mammary calcium transport and modulates neonatal skeletal growth and turnover cooperatively with calcium. Am J Physiol Endocrinol Metab (2011) 0.82
Association between AAAG repeat polymorphism in the P3 promoter of the human parathyroid hormone (PTH)/PTH-related peptide receptor gene and adult height, urinary pyridinoline excretion, and promoter activity. J Clin Endocrinol Metab (2002) 0.81
CaSR-mediated interactions between calcium and magnesium homeostasis in mice. Am J Physiol Endocrinol Metab (2013) 0.81
Calcium sensing receptor absence delays postnatal brain development via direct and indirect mechanisms. Mol Neurobiol (2013) 0.81
Ihh enhances differentiation of CFK-2 chondrocytic cells and antagonizes PTHrP-mediated activation of PKA. J Cell Sci (2002) 0.81
Fracture risk prediction: importance of age, BMD and spine fracture status. Bonekey Rep (2013) 0.81
The calcium-sensing receptor and 25-hydroxyvitamin D-1alpha-hydroxylase interact to modulate skeletal growth and bone turnover. J Bone Miner Res (2010) 0.81
Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification. Clin Chem (2010) 0.81